Herpes Simplex Virus (HSV) Study

The Herpes Simplex Virus 2 (HSV-2) is a chronic long-term condition that causes genital ulcers.  It is widely prevalent, with an estimated 13.2% or 491.5 million people aged 15-49 years worldwide living with HSV-2. 

HSV-2 can lie dormant in nerve cells and become active again with periodic viral shedding episodes that cause unpleasant recurrent symptoms in some people as well as the risk of transmission to sexual partners. 

Current treatment with antiviral medication is only partially effective in preventing recurrences and transmission to others. There is need for more potent, long-acting antiviral therapy.

Momentum Clinical Research are conducting a clinical study for a potential long-acting oral antiviral medication that aims to suppress recurrent episodes of genital herpes.

Participants will receive treatment over a 29 day period and will come into the clinic for a minimum of 18 appointments across 172 days. 

Your contribution to this study will help evaluate the safety and tolerability of a potential new medication that may improve the lives of people in our communities that suffer from this chronic condition and protect the sexual health of others.

 Register now and find out if this study is right for you.

This research is funded by Assembly Biosciences Inc. Approved by Northern B Ethics committee (19873)